OBJECTIVE: The aim of this study was to assess anatomical and functional outcomes 2 years after prolapse repair using vaginal mesh repair system. METHODS: Women enrolled in a 12-month observational study of outcomes after transvaginal mesh-augmented prolapse repair were invited to participate in an extended follow-up. Subjects completed questionnaires assessing pelvic symptoms, quality of life, global satisfaction, and a pelvic examination for anatomical support and mesh complications. RESULTS: Of 118 eligible women, 85 enrolled, 82 provided subjective data at 24 months, and pelvic examination/Pelvic Organ Prolapse Quantification data are available from 79 women. Total, anterior, and posterior Prolift kits were used in 47 (55%), 25 (29%), and 13 (15%), respectively. At baseline, most of the women had stage III prolapse (75%), with the anterior compartment constituting the leading edge in 71% of subjects. At 24 months, Pelvic Organ Prolapse Quantification measures were significantly improved from baseline in all compartments, with 51 (65%) stage 0/I, 25 (31%) stage II, 3 (4%) and stage III (P < 0.001), as were quality of life scores (P < 0.001), with the exception of sexual function. Symptomatic prolapse was reported by 7 (8.5%) women, of which 4 demonstrated prolapse in the nonoperated compartment. Three subjects (4%) reported persistent pelvic pain. The 2-year mesh exposure incidence was at least 13% (11/85). The proportion reporting dyspareunia was 28.9% (13/45) and was unchanged from baseline. The median global satisfaction was 9.3 (range 2.0-10.0). CONCLUSIONS: Anatomical support, symptom relief, and satisfaction are high 24 months after mesh-augmented vaginal prolapse repair, although mesh exposure and new onset prolapse of the nonoperated compartment are not uncommon.
OBJECTIVE: The aim of this study was to assess anatomical and functional outcomes 2 years after prolapse repair using vaginal mesh repair system. METHODS:Women enrolled in a 12-month observational study of outcomes after transvaginal mesh-augmented prolapse repair were invited to participate in an extended follow-up. Subjects completed questionnaires assessing pelvic symptoms, quality of life, global satisfaction, and a pelvic examination for anatomical support and mesh complications. RESULTS: Of 118 eligible women, 85 enrolled, 82 provided subjective data at 24 months, and pelvic examination/Pelvic Organ Prolapse Quantification data are available from 79 women. Total, anterior, and posterior Prolift kits were used in 47 (55%), 25 (29%), and 13 (15%), respectively. At baseline, most of the women had stage III prolapse (75%), with the anterior compartment constituting the leading edge in 71% of subjects. At 24 months, Pelvic Organ Prolapse Quantification measures were significantly improved from baseline in all compartments, with 51 (65%) stage 0/I, 25 (31%) stage II, 3 (4%) and stage III (P < 0.001), as were quality of life scores (P < 0.001), with the exception of sexual function. Symptomatic prolapse was reported by 7 (8.5%) women, of which 4 demonstrated prolapse in the nonoperated compartment. Three subjects (4%) reported persistent pelvic pain. The 2-year mesh exposure incidence was at least 13% (11/85). The proportion reporting dyspareunia was 28.9% (13/45) and was unchanged from baseline. The median global satisfaction was 9.3 (range 2.0-10.0). CONCLUSIONS: Anatomical support, symptom relief, and satisfaction are high 24 months after mesh-augmented vaginal prolapse repair, although mesh exposure and new onset prolapse of the nonoperated compartment are not uncommon.
Authors: R C Bump; A Mattiasson; K Bø; L P Brubaker; J O DeLancey; P Klarskov; B L Shull; A R Smith Journal: Am J Obstet Gynecol Date: 1996-07 Impact factor: 8.661
Authors: Chiara Ghetti; W Thomas Gregory; S Renee Edwards; Lesley N Otto; Amanda L Clark Journal: Am J Obstet Gynecol Date: 2005-07 Impact factor: 8.661
Authors: Victoria L Handa; Halina M Zyczynski; Linda Brubaker; Ingrid Nygaard; Nancy K Janz; Holly E Richter; Patricia A Wren; Morton B Brown; Anne M Weber Journal: Am J Obstet Gynecol Date: 2007-12 Impact factor: 8.661
Authors: Ingrid E Nygaard; Rebecca McCreery; Linda Brubaker; AnnaMarie Connolly; Geoff Cundiff; Anne M Weber; Halina Zyczynski Journal: Obstet Gynecol Date: 2004-10 Impact factor: 7.661
Authors: Alexis A Dieter; Marcella G Willis-Gray; Alison C Weidner; Anthony G Visco; Evan R Myers Journal: Int Urogynecol J Date: 2015-02-03 Impact factor: 2.894
Authors: Priyanka Gupta; James Payne; Kim A Killinger; Michael Ehlert; Jamie Bartley; Jason Gilleran; Judy A Boura; Larry T Sirls Journal: Int Urogynecol J Date: 2016-06-24 Impact factor: 2.894